# Jesús F. San Miguel

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jesus-f-san-miguel/

## Facts

| Field | Value |
| --- | --- |
| Citations | 129,300 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 160 |
| i10-index | 980 |
| Last Known Institution | Navarre Institute of Health Research |
| OpenAlex ID | https://openalex.org/A5020989412 |
| ORCID iD | https://orcid.org/0000-0002-9183-4857 |
| Works | 2,283 |

## Researcher papers

- [International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma](https://scholariq.org/papers/international-myeloma-working-group-consensus-criteria-for-response-and-minimal/)
- [Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma](https://scholariq.org/papers/idecabtagene-vicleucel-in-relapsed-and-refractory-multiple-myeloma/)
- [Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease](https://scholariq.org/papers/standardized-rt-pcr-analysis-of-fusion-gene-transcripts-from-chromosome/)
- [Teclistamab in Relapsed or Refractory Multiple Myeloma](https://scholariq.org/papers/teclistamab-in-relapsed-or-refractory-multiple-myeloma/)
- [Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study](https://scholariq.org/papers/teclistamab-a-b-cell-maturation-antigen-cd3-bispecific-antibody-in-patients-with/)
- [Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-plus-pomalidomide-and-dexamethasone-for-patients-with-relapsed-or/)
- [LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma](https://scholariq.org/papers/locommotion-a-prospective-non-interventional-multinational-study-of-real-life/)
- [The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma](https://scholariq.org/papers/the-mechanism-of-action-of-the-anti-cd38-monoclonal-antibody-isatuximab-in/)
- [International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation](https://scholariq.org/papers/international-myeloma-working-group-guidelines-for-the-management-of-multiple/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [Navarre Institute of Health Research](https://scholariq.org/institutions/navarre-institute-of-health-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.